Germany’s Bayer (ETR: BAYN) has launched a double-blind, placebo-controlled mid-stage trial for its potential first-in-class anti-alpha2 antiplasmin (anti-α2ap) drug, BAY3018250, aimed at treating symptomatic proximal deep vein thrombosis (DVT). This advancement comes on the heels of a successful Phase I study.
The investigational antibody works by modulating the breakdown of thrombotic blood clots through the inhibition of α2ap, which in turn blocks plasmin’s thrombolytic activity. BAY3018250 also holds promise for other high-relevance medical indications.- Flcube.com
